Medix Biochemica Acquires ViroStat LLC

StatLab Medical Products Acquires BBC Biochemical

April 2, 2020

Medical Devices

StatLab Medical Products has acquired Mount Vernon, Washington-based BBC Biochemical to expand its manufacturing capabilities and broaden access to diagnostic supplies for anatomic pathology laboratories and OEM partners. The acquisition increases StatLab's capacity for formalin prefills and strengthens its international OEM business.

Medix Biochemica Group Acquires Bioresource Technology (BRT)

June 21, 2022

Biotechnology

Medix Biochemica has acquired a 100% stake in US-based Bioresource Technology (BRT) to expand its base matrix capabilities and strengthen its presence in the United States. BRT will be integrated into Medix Biochemica’s IVD Biomaterials Business Unit (St. Louis) while operations continue in Weston, Florida, and BRT leadership will serve as strategic advisors.

Sanofi to Acquire Vicebio for Up to $1.6 Billion

July 25, 2025

Biotechnology

Sanofi will acquire clinical-stage biopharmaceutical company Vicebio in a deal worth up to $1.6 billion, including $1.15 billion upfront and $450 million in milestone payments. Vicebio, created by Medicxi using the University of Queensland's Molecular Clamp technology, develops multivalent vaccines targeting respiratory viruses and recently advanced a bivalent RSV/hMPV candidate into Phase 1 trials.

Veristat Acquires Instat Clinical Research

October 19, 2023

Healthcare Services

Veristat, a full-service clinical research organization, has acquired Instat Clinical Research, a biometrics-focused CRO with teams in the United States and India. The deal expands Veristat's biometrics, data management, biostatistics, and statistical programming capabilities while adding offshore capacity to enable round-the-clock support for clinical studies.

BioIVT Acquires Valley Biomedical Products & Services

June 28, 2021

Medical Devices

BioIVT, a provider of research models and value-added research services, has acquired Valley Biomedical Products & Services, an FDA-registered manufacturer of in vitro diagnostics, sera, plasma and reagents based in Winchester, Virginia. The acquisition will expand BioIVT’s capabilities in IVD manufacturing and cell & gene therapy support by combining Valley Biomedical’s reagent and blood-product manufacturing with BioIVT’s donor centers and specimen services; BioIVT will continue operating the Winchester facility and retain its staff.

Merck & Co., Inc. Acquires VelosBio Inc.

November 5, 2020

Biotechnology

Merck & Co., Inc. will acquire all outstanding shares of clinical-stage biopharmaceutical company VelosBio for $2.75 billion in cash. The acquisition adds VelosBio's lead investigational antibody-drug conjugate VLS-101 and ROR1-directed pipeline assets to Merck's oncology portfolio and is expected to close by the end of 2020, subject to customary conditions.